文献速递类风湿关节炎其他结缔组织病

类风湿关节炎相关间质性肺病中生物及靶向合成DMARD的靶试验模拟

Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease.
PubMed 文献 · Semin Arthritis Rheum · 2026-03-25

本研究利用2006至2019年Medicare数据,对RA-ILD患者进行靶试验模拟,采用倾向评分匹配比较阿巴西普、JAK抑制剂、IL-6抑制剂和TNF抑制剂与利妥昔单抗起始者的结局。主要复合结局无显著差异,但阿巴西普和JAK抑制剂与较低死亡率相关。

要点

  • 与利妥昔单抗相比,阿巴西普、JAKi、IL-6i和TNFi的主要复合结局风险无显著差异。
  • 次要分析中,阿巴西普和JAKi与利妥昔单抗相比死亡率显著降低。
  • 仍需随机对照试验确定RA-ILD的最佳治疗。

核心结论

  • 在靶试验模拟中,利妥昔单抗与其他b/tsDMARDs的主要复合结局无统计学显著差异,但阿巴西普和JAKi与降低的死亡率相关。

研究设计与样本

  • 利用2006至2019年Medicare数据识别RA-ILD患者,采用观察性数据模拟靶试验,进行倾向评分匹配的队列分析。

主要发现

  • 阿巴西普(n=694)、JAKi(n=156)、IL-6i(n=389)和TNFi(n=734)起始者各与等量利妥昔单抗起始者进行倾向评分匹配。
  • 主要复合结局(呼吸住院、肺移植或死亡)风险比:阿巴西普HR 0.87(95%CI 0.75-1.00),JAKi HR 0.74(95%CI 0.51-1.08),IL-6i HR 1.08(95%CI 0.88-1.33),TNFi HR 1.09(95%CI 0.95-1.25)。
  • 次要分析中,与利妥昔单抗相比,阿巴西普(HR 0.84,95%CI 0.71-0.98)和JAKi(HR 0.62,95%CI 0.40-0.96)与较低死亡率相关。

临床怎么用

  • 对于RA-ILD患者,b/tsDMARD选择需个体化,阿巴西普和JAKi可能与较低死亡率相关,但主要复合结局无显著差异。

局限性

  • 观察性研究设计存在残余混杂可能,且结果需随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited clinical trial evidence guiding immunosuppressive medication use in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We evaluated the associations between different biologic and targeted synthetic DMARD (b/tsDMARD) treatments with outcomes in RA-ILD patients. METHODS: We identified RA-ILD patients using Medicare data from 2006 to 2019 and performed emulated target trials using observational data. Propensity score (PS) matched cohorts compared abatacept, janus kinase inhibitors (JAKi), IL-6 inhibitors (IL-6i), and tumor necrosis factor inhibitors (TNFi); each b/tsDMARD was compared in separate two-way comparisons to rituximab initiators using an intention-to-treat framework. The primary outcome was a composite of respiratory hospitalization, lung transplant, or death. We calculated hazard ratios using Cox proportional hazards regression. RESULTS: We analyzed RA-ILD patients initiating abatacept (n = 694), JAKi (n = 156), IL-6i (n = 389), or TNFi (n = 734), each PS-matched to an equal number of rituximab initiators. There were no statistically significant differences in the risk of the composite outcome of respiratory hospitalization, lung transplant, or death: abatacept (HR 0.87 95%CI 0.75-1.00), JAKi (HR 0.74 95%CI 0.51-1.08), IL-6i (HR 1.08 95%CI 0.88-1.33), and TNFi (HR 1.09 95%CI 0.95-1.25). In secondary analyses, abatacept (HR 0.84 95%CI 0.71-0.98) and JAKi (HR 0.62 95%CI 0.40-0.96) were associated with lower mortality compared to rituximab. CONCLUSIONS: In target trial emulations, there were no statistically significant differences between rituximab and other b/tsDMARDs for the primary composite outcome. However, abatacept and JAKi were associated with reduced mortality. Randomized controlled trials in RA-ILD are needed to determine optimal treatment.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. McDermott GC, Solomon DH, Sparks JA, et al. Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease. Semin Arthritis Rheum. 2026. PMID: 41990460. doi:10.1016/j.semarthrit.2026.152973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。